Patent ID: 6232327
Filing Date: 2001-05-15
Classification: A61K,A61P,C07D

Abstract:
A method of using an N-substituted indole-3-glyoxylamide of formula 1 as an antitumor agent, ##STR158##where the radicals R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Z have the following meanings:R=hydrogen, (C.sub.1 -C.sub.6)-alkyl, where the alkyl group is optionally mono- or polysubstituted by a phenyl ring and this phenyl ring for its part is optionally mono- or polysubstituted by halogen, (C.sub.1 -C.sub.6)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, by carboxyl groups, carboxyl groups esterified with C.sub.1 -C.sub.6 -alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups, benzyloxy groups or by a benzyl group which is mono- or polysubstituted in the phenyl moiety by (C.sub.1 -C.sub.6)-alkyl groups, halogen atoms or trifluoromethyl groups, orR is a benzyloxycarbonyl group or a tertiary-butoxycarbonyl radical (BOC radical), or an acetyl group,R.sub.1 is a pyridine structure of formula 2 ##STR159##or its N-oxide, where the pyridine structure is alternatively bonded to the ring carbon atoms 2, 3 and 4 and is optionally substituted by the substituents R.sub.5 and R.sub.6 ; R.sub.5 and R.sub.6 are identical or different and signify (C.sub.1 -C.sub.6)-alky, (C.sub.3 -C.sub.7)-cycloalkyl, (C.sub.1 -C.sub.6)-alkoxy, nitro, amino, hydroxyl, halogen, trifluoromethyl, ethoxycarbonylamino radical and a carboxyalkyloxy group in which the alkyl group has 1-4 C atoms;R.sub.2 is hydrogen or a (C.sub.1 -C.sub.6)-alkyl group, where the alkyl group is mono- or polysubstituted by halogen and phenyl, which for its part is optionally mono or polysubstituted by halogen, (C.sub.1 -C.sub.6)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, carboxyl groups, carboxyl groups esterified with C.sub.1 -C.sub.6 -alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups or benzyloxy groups, the (C.sub.1 -C.sub.6)-alkyl group is optionally substituted by the 2-quinolyl group and the 2-, 3- and 4-pyridyl structure, which are optionally in each case mono- or polysubstituted by halogen, (C.sub.1 -C.sub.4)-alkyl groups or (C.sub.1 -C.sub.4)-alkoxy groups, or R.sub.2 is an aroyl radical, where the aryl moiety on which the radical is based is a phenyl ring, which is optionally mono- or polysubstituted by halogen, (C.sub.1 -C.sub.6)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, carboxyl groups, carboxyl groups esterified with C.sub.1 -C.sub.6 -alkanols, trifluoromethyl groups, hydroxyl groups, methoxy groups, ethoxy groups or benzyloxy groups;R.sub.3 and R.sub.4 are identical or different and are hydrogen, (C.sub.1 -C.sub.6)-alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, (C.sub.1 -C.sub.6)-alkanoyl, (C.sub.1 -C.sub.6)-alkoxy, halogen and benzyloxy, or a nitro group, an amino group, a (C.sub.1 -C.sub.4)- mono or dialkyl-substituted amino group, or a (C.sub.1 -C.sub.6) alkoxycarbonylamino function or (C.sub.1 -C.sub.6)-alkoxycarbonylamino-(C.sub.1 -C.sub.6)-alkyl function; andZ is O or S;said method comprising administering said N-substituted indole-3-glyoxylamide or an acid addition salt or N-oxide thereof to a subject in need of antitumor treatment.